BioRender 图标

Oligodendrocyte (pre-myelinating)

Oligodendrocyte (pre-myelinating) - Editable icon of an inactivated oligodendrocyte before attachment to axon for myelination
[{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458340/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458340/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458341/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458341/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458342/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458342/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458343/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458343/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458344/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458344/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458345/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458345/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458346/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458346/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458347/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458347/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458348/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458348/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458349/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458349/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834a/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834a/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834b/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834b/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834c/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834c/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834d/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834d/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834e/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834e/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834f/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834f/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458350/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458350/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458351/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458351/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458352/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458352/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458353/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458353/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458354/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458354/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458355/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458355/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458356/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458356/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458357/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458357/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458358/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458358/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458359/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458359/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835a/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835a/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835b/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835b/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835c/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835c/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835d/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835d/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835e/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835e/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835f/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835f/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458360/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458360/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458361/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458361/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458362/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458362/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458363/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458363/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458364/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458364/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458365/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458365/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458366/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458366/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458367/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458367/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458368/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458368/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458369/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458369/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836a/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836a/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836b/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836b/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836c/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836c/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836d/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836d/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836e/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836e/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836f/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836f/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458370/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458370/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458371/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458371/5a7cc6a90d495d001444bc2d.png"}]
使用此图标 – 免费
注册无需信用卡。

此图标可在 BioRender 中完全编辑

  • 添加文本、形状及其他图标
  • 搜索 50,000 多种科学准确的图标
  • 重新着色并重新排列每一个图标、线条和标签
  • 导出或分享以满足任何使用需求
Scientist Avatars

加入 400 多万名科学家 的行列,制作可直接用于发表的图表

从图标到成品图表,只需几分钟

  • 搜索 来自 50,000 多个科学准确、经同行评审的图标
  • 自定义 添加标签、形状和更多图标——一切皆可完全编辑
  • 导出 或与协作者分享您的图表
    ‍

图标不合适?探索更多内容。

搜索涵盖 30 多个生命科学领域的 50,000 多个图标。

search icon
arrow-right
oligodendrocyte,oiigodendroglia,glial cell,myelin,myelination,neuron,neuroglia,pns,peripheral nervous system,axon,pre-myelinating oligodendrocyte,PMO
查看更多

尝试使用同义词,或注册以在应用中请求图标。

图像类型

Oligodendrocyte (pre-myelinating) icon JPEG

Oligodendrocyte (pre-myelinating) icon PNG

Oligodendrocyte (pre-myelinating) icon SVG

Oligodendrocyte (pre-myelinating) icon GIF

BioRender 图标常见问题解答

How are scientists using the Oligodendrocyte (pre-myelinating) icon in their work?

BioRender users often use the Oligodendrocyte (pre-myelinating) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

我可以在 BioRender 图表或科学插图中使用此图标吗?

Yes, the Oligodendrocyte (pre-myelinating) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Oligodendrocyte (pre-myelinating) icon customizable in BioRender?

Most icons in BioRender, including the Oligodendrocyte (pre-myelinating) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Oligodendrocyte (pre-myelinating) icon for publication or presentations?

Yes, figures containing the Oligodendrocyte (pre-myelinating) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Oligodendrocyte (pre-myelinating) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Oligodendrocyte (pre-myelinating) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

什么是 BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Oligodendrocyte (pre-myelinating) icon along with our library of more than 30,000 life science icons.

在 BioRender 中使用此图标

立即开始制作专业的科学图表
antibody elements3D Phospholipid illustration

正在寻找科学内容?

浏览超过 5 万个经同行评审、易于使用且免费的图标和模板。

立即寻找您的专属素材
x icon